Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Posts Tagged ‘NASDAQ:CYTK’
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the most active stocks to buy according to analysts.
11 Best Most Active Stocks To Buy According to Analysts
The Co-Chief Investment Strategist at John Hancock Investment Management, Emily Roland, believes that we're in a period of serious disinflation.
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Cytokinetics' First Quarter 2025 Conference Call. At this time, I would like to inform you that this call is being recorded.
10 Best High Short Interest Stocks to Buy Now
Aditya Bhave, BofA Securities head of US Economics, joined 'Power Lunch' on CNBC on April 17 to talk about whether tariffs are ultimately inflationary, disinflationary, or deflationary...
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2024 Earnings Call Transcript February 27, 2025Cytokinetics, Incorporated beats earnings expectations.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US.
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
10 Stocks That Analysts Are Talking About
Like any other informed investor, we are always on the hunt for stocks that analysts are talking about.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript November 6, 2024Cytokinetics, Incorporated misses on earnings expectations.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
7 Best Small Company Stocks To Invest In
The Fed's decision to cut interest rates by 50 basis points in September significantly impacted the market.
Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-...
7 Best Mid-Cap Healthcare Stocks To Buy Now
The healthcare industry is considered to be a fairly defensive sector due to its need.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2023 Earnings Call Transcript
Cytokinetics, Incorporated misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-1.03.
5 Best Russell 2000 Stocks To Buy According To Hedge Funds
In this article, we discuss 5 best Russell 2000 stocks to buy.
Cytokinetics, Incorporated (CYTK) Rose on Successful Clinical Trial
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2023 investor letter.
11 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts.
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Third Quarter 2023 Conference Call.
10 Biotech Stocks with Biggest Upside
In this article, we discuss 12 biotech stocks with biggest upside.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Second Quarter 2020 Conference Call.
10 Best Economic Recovery Stocks to Buy
In this piece, we will take a look at the ten best economic recovery stocks to buy.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2023 Earnings Call Transcript
Operator: Good afternoon and welcome ladies and gentlemen to Cytokinetics' First Quarter 2023 Conference Call.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call.
Is Cytokinetics (CYTK) a Good Long-Term Investment?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Is Cytokinetics, Inc. (CYTK) Going to Burn These Hedge Funds?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market...
Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need ...
Is CYTK Stock A Buy or Sell?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund
In this article, we will present the 10 best stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman.
Top 10 Healthcare Stocks To Buy for the Future
Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market.
Hedge Funds Keep Buying Cytokinetics, Inc. (CYTK)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Did Hedge Funds Make The Right Call On Cytokinetics, Inc. (CYTK) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Hedge Funds Have Never Been This Bullish On Cytokinetics, Inc. (CYTK)
In this article you are going to find out whether hedge funds think Cytokinetics, Inc. (NASDAQ:CYTK) is a good investment right now.
Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy?
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Here is What Hedge Funds Really Think About Cytokinetics, Incorporated (CYTK)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Hedge Fund and Insider Trading News: Michael Platt, Warren Buffett, Balyasny Asset Management, AQR Capital, Aspen Group Inc (ASPU), W&T Offshore, Inc. (WTI), and More
BOSTON (Reuters) - Balyasny Asset Management, a Chicago-based hedge fund that shed $4 billion in assets last year and cut 20% of its staff, was back in positive territory for ...
Did Hedge Funds Drop The Ball On Cytokinetics, Inc. (CYTK) ?
Hedge fund interest in Cytokinetics, Inc. (NASDAQ:CYTK) shares was flat at the end of last quarter and it wasn't that high to begin with. This is usually a negative indicator.
Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity.
